SCHEMBL22776540

SCHEMBL22776540

CCn1nc(C(=O)O)c2c(Cc3ccc(C(F)(F)F)cc3)cccc21

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PTGER4 P35408 2/20 0.42
▸ SRD5A2 P31213 1/20 0.40
▸ P2RY14 Q15391 2/20 0.37
▸ PTGDR2 Q9Y5Y4 3/20 0.37
▸ NPY5R Q15761 1/20 0.36
▸ PTGER1 P34995 1/20 0.36
▸ LDHA P00338 1/20 0.36
▸ LDHB P07195 1/20 0.36
▸ RORC P51449 1/20 0.35
▸ ASPH Q12797 1/20 0.35
▸ KDM8 Q8N371 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ BLM P54132 1/20 0.35
▸ PMP22 Q01453 1/20 0.35
▸ HCRTR1 O43613 1/20 0.35
▸ HCRTR2 O43614 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22791384 0.90 PTGER4 (0.38) PTGER4SRD5A2PTGDR2NPY5RKDM4E
SCHEMBL22776444 0.88 PTGER4 (0.39) PTGER4PTGDR2NPY5RRORCKDM4E
SCHEMBL22776589 0.88 PTGER4 (0.41) PTGER4SRD5A2P2RY14PTGDR2NPY5R
SCHEMBL29527167 0.83 LDHA (0.39) PTGER4SRD5A2P2RY14NPY5RLDHA
SCHEMBL22776609 0.83 LDHA (0.39) PTGER4SRD5A2P2RY14NPY5RLDHA
SCHEMBL22776587 0.83 PTGER4 (0.54) PTGER4
SCHEMBL22776588 0.83 PTGER4 (0.54) PTGER4
SCHEMBL22791289 0.81 PTGDR2 (0.41) PTGER4PTGDR2RORC
SCHEMBL29614425 0.81 PTGER4 (0.36) PTGER4P2RY14PTGDR2NPY5RHCRTR1
SCHEMBL27721950 0.80 ALDH1A1 (0.44) RORCKDM4EALDH1A1LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220324803-A1 PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF TEON THERAPEUTICS INC (US) 2022-10-13 — — US disclosed
EP-3983412-A1 PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF Teon Therapeutics, Inc. (US) 2022-04-20 — — EP disclosed
CN-114206866-A Prostaglandin E2Receptor 4 antagonists and uses thereof 泰昂治疗公司 2022-03-18 — — CN disclosed
WO-2020251957-A1 PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF TEON THERAPEUTICS, INC. (US) 2020-12-17 — — WO disclosed
WO-2020251957-A1 PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF TEON THERAPEUTICS, INC. (US) 2020-12-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220324803-A1 PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF PTGER4, PTGER1, PTGER2 PTGER4 1/4885SRD5A2 487/4885P2RY14 134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback